Time filter

Source Type

New Delhi, India

Shrivastav M.,Medtronic | Padte S.,Medtronic | Arora V.,Max Super Specialty Hospital | Biffi M.,University of Bologna
Expert Review of Cardiovascular Therapy | Year: 2014

Electrocardiographic monitoring represents one of the most reliable and time-tested methods for reducing ambiguity in cardiac arrhythmia diagnosis. In India, the resting ECG is generally the first tool of choice for in-clinic diagnosis. The external loop recorder (ELR) is another useful tool that compounds the advantages of traditional tools by coupling ambulatory monitoring with a long-term window. Thus, the objective was to test the use of a 7-day ELR for arrhythmia diagnosis in India for a broad range of presenting symptoms. In this study set in the Indian healthcare environment, an auto-triggered, wireless patch-type ELR was used with 125 patients (62.5 ± 16.7 years, 76 males) presenting a broad range of symptoms. Eighty percent of the symptoms were related to syncope, presyncope or palpitations. Patients were administered an ELR for 7-28 days depending on the physician's prescription. Prespecified significant arrhythmias included sinus pause >2 s, symptomatic bradycardia <40 b.p.m., second-degree (and higher) AV block, complete heart block, ventricular fibrillation, sustained/nonsustained ventricular tachycardia (>3 beats), atrial fibrillation (chronic or paroxysmal), atrial flutter and supraventricular tachycardia (SVT) >130 b.p.m. Diagnostic yield was 38% when a stringent tabulation methodology considering only clinically significant arrhythmia was used. When first-degree AV block, premature atrial and ventricular beats, couplets (both atrial and ventricular in origin), bigeminy or trigeminy, or sudden changes in rate (noted as sinus arrhythmia) were included in the calculation, diagnostic yield was 80%. Patient compliance was 98%; patients wore the patch for the entire prescribed monitoring period without disruption. Seventy percent of the reported symptoms corresponded with an arrhythmia. Use of the ELR led to therapy change in 24% of patients: 15 patients went on to receive an implantable cardioverter defibrillator or pacemaker, 4 received ablation therapy and 11 altered their medication after diagnosis. This study demonstrates that a high diagnostic yield for clinically significant arrhythmias and high patient compliance can be achieved with a wearable patch monitor in Indian patients suffering from a variety of symptoms. © 2014 Informa UK Ltd.

Sharma A.,Max Super Specialty Hospital | Malaviya A.N.,ISIC Superspeciality Hospital
Indian Journal of Rheumatology | Year: 2014

Objective: The present study was carried out to test if Visser et al's 2002 diagnostic criteria for acute sarcoid arthritis (Löfgren syndrome) are applicable in India, a country with high burden of tuberculosis. Methods: 30 consecutive patients classified as acute sarcoid arthritis according to Visser et al's criteria were included. They were screened for TB with standard Mantoux test, radiograph of chest and if found normal, contrast enhanced computerized tomography (CE-CT) of thorax. Results: 24 of 30 patients showed a negative Mantoux test as well as normal chest radiograph and CE-CT. These patients were labeled as acute sarcoid arthritis. There were, 6 (20%) patients who had one or more features of TB by way of a positive Mantoux test and/or mediastinal lymphadenopathy with central necrosis, or asymmetrical hilar lymphadenopathy. The latter patients were diagnosed as having Poncet's disease, a parainfectious arthritis associated with the presence of tuberculosis at a distant site way from musculoskeletal system. Therapeutic response to low-dose glucocorticoid, hydroxychloroquine and low-dose methotrexate produced dramatic results among those diagnosed with acute sarcoid arthritis. On the other hand, those diagnosed as having Poncet's disease were given standard anti-TB drugs with excellent response. Conclusion: In a country with high burden of TB like India Visser et al's clinical criteria for the diagnosis of acute sarcoid arthritis (Löfgren syndrome) may not be very specific; TB must be ruled out before diagnosing acute sarcoid arthritis (Löfgren syndrome). Copyright © 2014, Indian Rheumatology Association. All rights reserved.

A patient on follow-up post surgery for carcinoma breast, presented with a nodule under the surgical scar. The sinister eventuality of recurrent carcinoma was clinically considered first. The lesion was biopsied and the histopathology was diagnostic of pseudoangiomatous stromal hyperplasia tumour. The nodule was excised and the patient's clinical denouement has been uneventful in the 4 months which have elapsed after this event.

Weaver M.S.,St Jude Childrens Research Hospital | Arora R.S.,Max Super Specialty Hospital | Howard S.C.,St Jude Childrens Research Hospital | Salaverria C.E.,Centro Medico Ayudame a Vivir | And 3 more authors.
Pediatric Blood and Cancer | Year: 2015

Treatment abandonment, the failure to complete therapy that is required for definitive disease control, frequently causes treatment failure for pediatric patients in low- and middle-income countries with chronic conditions, particularly cancer. Other forms of incomplete treatment affecting children in all settings, such as nonadherence and loss to follow-up, are often confused with treatment abandonment. Unclear definitions of incomplete treatment dramatically affect reported outcomes. To facilitate disease-specific and cross-sector analyses, we outline a practical approach to categorize forms of incomplete treatment, present distinct semantic categories with case examples and provide an algorithm that could be tailored to disease- and context-specific needs. Pediatr Blood Cancer 2015;62:565-570. © 2015 Wiley Periodicals, Inc.

Bhargava A.,Max Super Specialty Hospital
Expert Review of Endocrinology and Metabolism | Year: 2015

By the year 2030, diabetes mellitus will globally become the seventh leading cause of death. Currently, 382 million individuals worldwide have diabetes mellitus, with 80% residing in low- and middle-income countries. At present, Type 2 diabetes mellitus (T2DM) accounts for 85-95% of the diabetes burden in high-income countries. Alarmingly, this figure may be higher in the low- and middle-income nations. In an effort to combat this silent but deadly disease, pharmaceutical manufacturers have developed a host of different agents, each targeting a specific biochemical pathway. Among the most recent additions to this armament is linagliptin/metformin HCl, a fixed combination therapy compound manufactured by Boehringer Ingelheim. This novel formulation combines metformin, an insulin sensitizer, with linagliptin, a dipeptidyl peptidase-4 enzyme inhibitor. This review will discuss the pharmacokinetic properties of this molecule, assess clinical efficacy and gauge its place in the treatment algorithm for T2DM. © Informa UK, Ltd.

Discover hidden collaborations